Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 388 matching trials from the live ClinicalTrials.gov search.
Filters: "early Alzheimer" Condition: Alzheimer's Disease Clear all
Completed Phase 3 Interventional

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

NCT05463731
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Remternetug (IV), Remternetug (SC), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
73
States / cities
Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated No phase listed Observational

Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone

NCT03762902
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Lifegraph Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Detroit, Michigan • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease

NCT05052866
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Social Robot
Behavioral
Lead sponsor
DreamFace Technologies, LLC
Industry
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
BMS-986446, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
119
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Senicapoc in Alzheimer's Disease

NCT04804241
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Senicapoc, Placebo Tablet
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
55 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Sacramento, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Not yet recruiting Not applicable Interventional

CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI

NCT07866768
View directory record Official record
Conditions
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of ASN51 in Adults With Early Alzheimer's Disease

NCT06677203
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ASN51, Placebo
Drug
Lead sponsor
Asceneuron S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Clermont, Florida • Lady Lake, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

NCT03367403
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo, LY3202626
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Old School Hip Hop: Parent Follow-Up & Spanish Speakers Inclusion

NCT06699589
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Old SCHOOL Hip-Hop (Dementia Education), My Plate (Nutrition Education)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

NCT03560960
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Markers of Cognitive Change and Alzheimer s Disease

NCT01867346
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
2,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Early-onset Dementia

NCT04906863
View directory record Official record
Conditions
Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
Interventions
Blood draw, Neurocognitive testing, Medical questionnaire
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

NCT06223360
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 89 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Montelukast Therapy on Alzheimer's Disease

NCT03991988
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Montelukast, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ScentAware and OCT in MCI vs HC

NCT06377241
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
ScentAware, UPSIT
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Phase 1 Interventional

Study of AV-1959D, an Amyloid Beta Vaccine

NCT05642429
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AV-1959D, Placebo
Biological
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
60 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Newport Beach, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Not applicable Interventional

Early-Stage Partner in Care Living Alone Plus

NCT06962111
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions
Psychoeducational skills training intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

NCT05040217
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
AAV2-BDNF Gene Therapy, AAV2-BDNF Gene Therapy
Genetic · Biological
Lead sponsor
Mark Tuszynski
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Detecting an Early Response to Donepezil With Measures of Visual Attention

NCT03073876
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 13, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NCT03389698
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 13, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 13, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Plaque and Tangle Imaging in Aging and Dementia

NCT00355498
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

NCT04122001
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
Interventions
Active, in-person HD-tDCS or active remote tDCS, Sham, Word List Learning Intervention (WordLLI)
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 13, 2026, 7:14 PM EDT